Xintela AB (publ) 2,13
Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. It develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. The company is developing Xintela Assay for Cell Therapy (XACT), an analytical test for cell therapy. It also offers XSTEM-OA, a stem cell-based product for the treatment of osteoarthritis in humans. In addition, the company develops stem cell-based products for animals. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden. Læs mere
Kr. 204M Markedsværdi
Kr. 2,1M Omsætning
Bioteknologi Industri
Sverige Hjemland
xintela.se Hjemmeside